Omega-3 fatty acids modulate neonatal cytokine response to endotoxin

Area of Science:

• Immunology
• Neonatal Medicine
• Nutritional Science

Background:

• Neonatal immune responses are characterized by an uncompensated pro-inflammatory state, increasing susceptibility to infection and inflammation-related morbidity.
• Long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs) are crucial for immune system development and function.

Purpose of the Study:

• To investigate the effects of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) on cytokine secretion in response to lipopolysaccharide (LPS) in neonatal models.
• To assess the potential of n-3 PUFAs as a prophylactic or therapeutic agent to modulate neonatal inflammatory responses.

Main Methods:

• THP-1 monocytes and neonatal cord blood (CB) cells were pre-treated with varying concentrations of DHA or EPA.
• Cytokine secretion (IL-6, IL-10, IL-12, TNF-α, IL-1β, IL-8) was measured following low-concentration lipopolysaccharide (LPS) stimulation.
• DHA's effects were evaluated both before and after LPS exposure in isolated CB mononuclear cells to assess therapeutic potential.

Main Results:

• Pre-treatment with n-3 PUFAs significantly reduced IL-6, IL-10, and IL-12 secretion in THP-1 cells.
• DHA, more effectively than EPA, reduced TNF-α secretion in THP-1 cells and inhibited IL-12 in whole CB.
• Physiological concentrations of DHA significantly inhibited TNF-α, IL-6, IL-1β, and IL-8 secretion in CB cells, demonstrating both prophylactic and therapeutic effects.

Conclusions:

• Low-concentration DHA administration can effectively modulate neonatal cytokine responses to LPS.
• These findings provide proof-of-concept for using n-3 PUFAs to attenuate or resolve neonatal inflammatory responses.
• DHA shows promise as a potential therapeutic agent for managing inflammatory conditions in newborns.